NASDAQ · TVTX
Travere Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TVTX: Nov 02, 2026
Travere Therapeutics, Inc. Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.25. The reported EPS for the same quarter last year was $0.28.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.25 | $0.10 | $-0.79 | 4 |
| Dec 2026 | $0.27 | $0.74 | $-0.04 | 5 |
| Mar 2027 | $0.47 | $0.94 | $0.01 | 2 |
| Jun 2027 | $0.70 | $1.23 | $0.17 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Oct 28, 4:20 PM EDTVanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesVanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 9:00 AM EDTCytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 22, 10:27 AM EDTAstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyAZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
- Zacks · Oct 22, 9:00 AM EDTEarnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineTravere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Sep 14, 9:37 AM EDTBiotech Stocks At 52-Week Highs – TXG, OBIO, AVAH, OSCR, LFST, TVTX(RTTNews) – The biotech stocks listed below reached a new 52-week high on September 11, 2026, owing to upcoming clinical readouts and positive financial results. 10x Genomics Inc. (TXG) 10x Genomics is a life science technology company that specializes in developing various a
- RTTNews · Sep 11, 7:24 AM EDTShow Me The Money: Filspari Powers Travere Therapeutics' Growth(RTTNews) – Shares of Travere Therapeutics Inc. (TVTX) touched a 52-week high of $68.59 yesterday, reflecting the meaningful progress made across its key growth areas and the continued momentum in its business.
- RTTNews · Sep 11, 5:37 AM EDTBiotech Stocks At 52-Week Highs – OBIO, AVAH, TVTX, TXG, LFST(RTTNews) – The following biotech stocks reached a 52-week high on September 10, 2026, driven by significant clinical developments or financial progress. Orchestra BioMed Holdings Inc. (OBIO) Orchestra BioMed is a biomedical company specializing in developing therapies for va
- RTTNews · Sep 4, 5:15 AM EDTBiotech Stocks At 52-Week Highs – ATTO, HALO, IKT, TVTX, ATRC(RTTNews) – The following biotech stocks reached a 52-week high on September 3, 2026, as various clinical trials reported financial results and reached certain regulatory milestones.
- MarketBeat · Aug 18, 6:01 AM EDTTravere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline3 Under-the-Radar Healthcare CompaniesTravere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently
- The Motley Fool · Aug 11, 8:13 PM EDTTravere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 7, 8:04 AM EDTTravere Q2 Loss Widens Despite FILSPARI Sales Surge; Phase 4 SPARLIGHT Study Set To Begin In H2 '26(RTTNews) – Travere Therapeutics Inc. (TVTX), a biopharmaceutical company, released second quarter financial results on Wednesday, and provided updates on various drug candidates currently in the pipeline.
- RTTNews · Aug 6, 4:54 AM EDTBiotech Stocks At 52-Week Highs – BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Travere Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.